Inhaled Treprostinil
Idiopathic Pulmonary Fibrosis · Prostacyclin Analog
Clinical trials
3
Mechanism
Prostacyclin Analog
Development stage
Phase III (FDA filing 2026)
Evidence level
Level 1 (Phase III Positive)
Developer
United Therapeutics
Overview
TETON-1 and TETON-2 Phase III: inhaled treprostinil significantly slowed FVC decline and reduced clinical worsening at 52 weeks in IPF. Already FDA-approved for PAH/PH-ILD. FDA submission for IPF expected summer 2026.
Inhaled Treprostinil clinical trials
Explore related
Medical disclaimer. This page summarizes research about Inhaled Treprostinil for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.